AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Nucleonics, Inc., a biotechnology company focused on the development of novel RNA interference-based (RNAi) therapeutics, has acquired an exclusive license from the University of California to intellectual property covering a class of promoters that many scientists consider the "gold standard" for transcribing expressed interfering RNAs.
Specifically, the license gives Nucleonics exclusive worldwide rights to the use of all eukaryotic RNA Pol III promoters, including human promoters, within the field of expressed interfering RNA for any human therapeutic indication. Moreover, the license covers the delivery of these promoters by either plasmid DNA or viral vectors. Through this license, ...